Unum Therapeutics Inc. (UMRX)
Stock Price:
$0.440 USD
-0.030 (-6.38%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
13.71M |
| Revenue (ttm) |
26.48M |
| Net Income (ttm) |
-26.24M |
| Shares Out |
31.16M |
| EPS (ttm) |
-0.86 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$0.440 |
| Previous Close |
$0.470 |
| Change ($) |
-0.030 |
| Change (%) |
-6.38% |
| Day's Open |
0.480 |
| Day's Range |
0.430 - 0.480 |
| Day's Volume |
359,076 |
| 52-Week Range |
0.295 - 2.840 |
More Stats
| Market Cap |
13.71M |
| Enterprise Value |
n/a |
| Earnings Date (est) |
Aug 17, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
31.16M |
| Float |
14.97M |
| EPS (basic) |
-0.85 |
| EPS (diluted) |
-0.86 |
| FCF / Share |
-1.25 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
397,541 |
| Short Ratio |
0.72 |
| Short % of Float |
2.32% |
| Beta |
1.33 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
0.52 |
| PB Ratio |
0.59 |
| Revenue |
26.48M |
| Operating Income |
-26.48M |
| Net Income |
-26.24M |
| Free Cash Flow |
-37.68M |
| Net Cash |
25.21M |
| Net Cash / Share |
0.81 |
| Gross Margin |
-80.11% |
| Operating Margin |
-100.00% |
| Profit Margin |
-99.10% |
| FCF Margin |
-142.30% |
| ROA |
-25.76% |
| ROE |
-69.97% |
| ROIC |
2,281.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (1)
| Buy |
0 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Low
1.00
Current: 0.440
High
1.00
Target: 1.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | 22.50 | 9.73 | 8.36 | 6.36 | 2.99 |
| Revenue Growth | 131.14% | 16.44% | 31.55% | 112.83% | - |
| Gross Profit | 22.50 | 9.73 | 8.36 | 6.36 | 2.99 |
| Operating Income | -32.18 | -36.01 | -26.15 | -19.07 | -6.59 |
| Net Income | -31.83 | -34.53 | -25.49 | -18.12 | -6.59 |
| Shares Outstanding | 30.48 | 24.90 | 10.19 | 10.19 | 10.19 |
| Earnings Per Share | -1.04 | -1.39 | -2.51 | -1.78 | -0.65 |
| Operating Cash Flow | -41.51 | -32.49 | -25.84 | -18.64 | 17.72 |
| Capital Expenditures | 0.17 | -0.55 | -0.91 | -3.31 | -1.99 |
| Free Cash Flow | -41.34 | -33.04 | -26.75 | -21.95 | 15.72 |
| Cash & Equivalents | 38.68 | 79.85 | 42.29 | 69.76 | 0.00 |
| Total Debt | 6.03 | - | - | - | - |
| Net Cash / Debt | 32.65 | 79.85 | 42.29 | 69.76 | 0.00 |
| Assets | 49.42 | 85.93 | 49.12 | 75.55 | - |
| Liabilities | 17.66 | 25.69 | 20.81 | 23.16 | - |
| Book Value | 31.76 | 60.23 | -48.85 | -24.70 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Unum Therapeutics Inc. |
| Country |
United States |
| Employees |
29 |
| CEO |
Charles Wilson |
Stock Information
| Ticker Symbol |
UMRX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: UMRX |
| IPO Date |
March 29, 2018 |
Description
Unum Therapeutics Inc., a biopharmaceutical company, develops and commercializes immunotherapy products for cancer. The company is developing ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ non-Hodgkin lymphoma (r/r NHL). Its product portfolio also includes ACTR087 used in combination with rituximab that is in Phase I clinical trials to treat adult patients with r/r NHL; ACTR087 used in combination with SEA-BCMA, which is in Phase I clinical trials for treating patients with r/r multiple myeloma; ACTR707 used in combination with trastuzumab that is in Phase I clinical trials for treating HER2+ solid tumor cancers; and BOXR1030, which is in pre-clinical stage, targets glypican-3 that improve T cell functionality in the solid tumor microenvironment. Unum Therapeutics Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.